CRINETICS PHARMACEUTICALS IN (CRNX) Stock Fundamental Analysis

NASDAQ:CRNX • US22663K1079

42.7 USD
-1.38 (-3.13%)
At close: Feb 13, 2026
42.7 USD
0 (0%)
After Hours: 2/13/2026, 8:01:08 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to CRNX. CRNX was compared to 191 industry peers in the Pharmaceuticals industry. While CRNX has a great health rating, there are worries on its profitability. While showing a medium growth rate, CRNX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • CRNX had negative earnings in the past year.
  • In the past year CRNX has reported a negative cash flow from operations.
  • CRNX had negative earnings in each of the past 5 years.
  • In the past 5 years CRNX always reported negative operating cash flow.
CRNX Yearly Net Income VS EBIT VS OCF VS FCFCRNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

  • With a Return On Assets value of -35.38%, CRNX perfoms like the industry average, outperforming 46.60% of the companies in the same industry.
  • CRNX's Return On Equity of -39.46% is in line compared to the rest of the industry. CRNX outperforms 57.07% of its industry peers.
Industry RankSector Rank
ROA -35.38%
ROE -39.46%
ROIC N/A
ROA(3y)-33.7%
ROA(5y)-34.4%
ROE(3y)-38.05%
ROE(5y)-38.05%
ROIC(3y)N/A
ROIC(5y)N/A
CRNX Yearly ROA, ROE, ROICCRNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CRNX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRNX Yearly Profit, Operating, Gross MarginsCRNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K -80K -100K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • CRNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CRNX has been increased compared to 1 year ago.
  • The number of shares outstanding for CRNX has been increased compared to 5 years ago.
  • There is no outstanding debt for CRNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRNX Yearly Shares OutstandingCRNX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CRNX Yearly Total Debt VS Total AssetsCRNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

2.2 Solvency

  • CRNX has an Altman-Z score of 18.48. This indicates that CRNX is financially healthy and has little risk of bankruptcy at the moment.
  • CRNX has a Altman-Z score of 18.48. This is amongst the best in the industry. CRNX outperforms 86.39% of its industry peers.
  • CRNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 18.48
ROIC/WACCN/A
WACC9.25%
CRNX Yearly LT Debt VS Equity VS FCFCRNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

  • A Current Ratio of 15.12 indicates that CRNX has no problem at all paying its short term obligations.
  • CRNX has a Current ratio of 15.12. This is amongst the best in the industry. CRNX outperforms 85.34% of its industry peers.
  • A Quick Ratio of 15.12 indicates that CRNX has no problem at all paying its short term obligations.
  • CRNX has a better Quick ratio (15.12) than 85.86% of its industry peers.
Industry RankSector Rank
Current Ratio 15.12
Quick Ratio 15.12
CRNX Yearly Current Assets VS Current LiabilitesCRNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • CRNX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -21.45%.
  • CRNX shows a strong growth in Revenue. In the last year, the Revenue has grown by 47.74%.
  • The Revenue has been decreasing by -2.68% on average over the past years.
EPS 1Y (TTM)-21.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-43.75%
Revenue 1Y (TTM)47.74%
Revenue growth 3Y-1.28%
Revenue growth 5Y-2.68%
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, CRNX will show a very strong growth in Earnings Per Share. The EPS will grow by 22.31% on average per year.
  • The Revenue is expected to grow by 273.06% on average over the next years. This is a very strong growth
EPS Next Y-36.07%
EPS Next 2Y-17.78%
EPS Next 3Y-0.81%
EPS Next 5Y22.31%
Revenue Next Year270.54%
Revenue Next 2Y506.63%
Revenue Next 3Y403.51%
Revenue Next 5Y273.06%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CRNX Yearly Revenue VS EstimatesCRNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2B 4B 6B
CRNX Yearly EPS VS EstimatesCRNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 10 20 30 40

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CRNX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRNX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRNX Price Earnings VS Forward Price EarningsCRNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRNX Per share dataCRNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17.78%
EPS Next 3Y-0.81%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • CRNX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CRINETICS PHARMACEUTICALS IN

NASDAQ:CRNX (2/13/2026, 8:01:08 PM)

After market: 42.7 0 (0%)

42.7

-1.38 (-3.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)02-26
Inst Owners115.45%
Inst Owner Change-0.2%
Ins Owners1.71%
Ins Owner Change3.94%
Market Cap4.05B
Revenue(TTM)1.53M
Net Income(TTM)-423.10M
Analysts84.55
Price Target86.34 (102.2%)
Short Float %16.35%
Short Ratio12.09
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-8.77%
Min EPS beat(2)-9.79%
Max EPS beat(2)-7.76%
EPS beat(4)1
Avg EPS beat(4)-5.74%
Min EPS beat(4)-9.79%
Max EPS beat(4)2.94%
EPS beat(8)1
Avg EPS beat(8)-6.07%
EPS beat(12)1
Avg EPS beat(12)-6.18%
EPS beat(16)2
Avg EPS beat(16)-6.92%
Revenue beat(2)1
Avg Revenue beat(2)310.54%
Min Revenue beat(2)-61.44%
Max Revenue beat(2)682.52%
Revenue beat(4)2
Avg Revenue beat(4)202.6%
Min Revenue beat(4)-100%
Max Revenue beat(4)682.52%
Revenue beat(8)3
Avg Revenue beat(8)91.58%
Revenue beat(12)7
Avg Revenue beat(12)151.74%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.61%
PT rev (3m)2.86%
EPS NQ rev (1m)-1.05%
EPS NQ rev (3m)-6.72%
EPS NY rev (1m)1.23%
EPS NY rev (3m)-2.51%
Revenue NQ rev (1m)22.54%
Revenue NQ rev (3m)38.18%
Revenue NY rev (1m)14.03%
Revenue NY rev (3m)15.04%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2639.61
P/FCF N/A
P/OCF N/A
P/B 3.78
P/tB 3.78
EV/EBITDA N/A
EPS(TTM)-4.53
EYN/A
EPS(NY)-5.15
Fwd EYN/A
FCF(TTM)-3.75
FCFYN/A
OCF(TTM)-3.69
OCFYN/A
SpS0.02
BVpS11.3
TBVpS11.3
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -35.38%
ROE -39.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.7%
ROA(5y)-34.4%
ROE(3y)-38.05%
ROE(5y)-38.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 171.91%
Cap/Sales 412.57%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.12
Quick Ratio 15.12
Altman-Z 18.48
F-Score3
WACC9.25%
ROIC/WACCN/A
Cap/Depr(3y)244.79%
Cap/Depr(5y)160.44%
Cap/Sales(3y)173.94%
Cap/Sales(5y)166.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-43.75%
EPS Next Y-36.07%
EPS Next 2Y-17.78%
EPS Next 3Y-0.81%
EPS Next 5Y22.31%
Revenue 1Y (TTM)47.74%
Revenue growth 3Y-1.28%
Revenue growth 5Y-2.68%
Sales Q2Q%N/A
Revenue Next Year270.54%
Revenue Next 2Y506.63%
Revenue Next 3Y403.51%
Revenue Next 5Y273.06%
EBIT growth 1Y-55.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-41.89%
EBIT Next 3Y-5.67%
EBIT Next 5YN/A
FCF growth 1Y-113.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-114.54%
OCF growth 3YN/A
OCF growth 5YN/A

CRINETICS PHARMACEUTICALS IN / CRNX FAQ

What is the ChartMill fundamental rating of CRINETICS PHARMACEUTICALS IN (CRNX) stock?

ChartMill assigns a fundamental rating of 4 / 10 to CRNX.


Can you provide the valuation status for CRINETICS PHARMACEUTICALS IN?

ChartMill assigns a valuation rating of 0 / 10 to CRINETICS PHARMACEUTICALS IN (CRNX). This can be considered as Overvalued.


What is the profitability of CRNX stock?

CRINETICS PHARMACEUTICALS IN (CRNX) has a profitability rating of 1 / 10.